Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Cash from Operations (2016 - 2025)

Spero Therapeutics' Cash from Operations history spans 10 years, with the latest figure at 8351000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 64.31% year-over-year to 8351000.0; the TTM value through Dec 2025 reached 12624000.0, up 46.15%, while the annual FY2025 figure was 12624000.0, 46.15% up from the prior year.
  • Cash from Operations reached 8351000.0 in Q4 2025 per SPRO's latest filing, down from 17422000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 44482000.0 in Q4 2022 to a low of 28223000.0 in Q1 2022.
  • Average Cash from Operations over 5 years is 7057050.0, with a median of 14166000.0 recorded in 2021.
  • Peak YoY movement for Cash from Operations: surged 1763.01% in 2023, then crashed 167.4% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 27349000.0 in 2021, then skyrocketed by 262.65% to 44482000.0 in 2022, then crashed by 139.33% to 17493000.0 in 2023, then tumbled by 33.77% to 23401000.0 in 2024, then skyrocketed by 64.31% to 8351000.0 in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Cash from Operations are 8351000.0 (Q4 2025), 17422000.0 (Q3 2025), and 17693000.0 (Q2 2025).